CIBC reissued their outperform rating on shares of Urogen Pharma (NASDAQ:URGN) in a report released on Wednesday, November 15th. CIBC currently has a $51.00 target price on the stock, up from their prior target price of $32.00.
Several other research analysts also recently weighed in on URGN. Oppenheimer set a $32.00 target price on shares of Urogen Pharma and gave the stock a buy rating in a research report on Monday, August 14th. Zacks Investment Research downgraded shares of Urogen Pharma from a buy rating to a hold rating in a research report on Friday, August 18th. Raymond James Financial downgraded shares of Urogen Pharma from an outperform rating to a market perform rating in a research report on Wednesday, November 15th. UBS downgraded shares of Urogen Pharma from an outperform rating to a market perform rating in a research report on Wednesday, November 15th. Finally, Jefferies Group boosted their price objective on shares of Urogen Pharma from $27.00 to $37.00 and gave the company a buy rating in a research report on Monday, October 9th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $36.80.
Shares of Urogen Pharma (NASDAQ URGN) traded up $0.78 on Wednesday, hitting $40.43. 212,279 shares of the stock traded hands, compared to its average volume of 70,141. Urogen Pharma has a 12 month low of $13.01 and a 12 month high of $44.63.
In other Urogen Pharma news, major shareholder Proquest Investments Iv, L.P. sold 209,298 shares of Urogen Pharma stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $40.60, for a total value of $8,497,498.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Hedge funds and other institutional investors have recently bought and sold shares of the business. State of Tennessee Treasury Department acquired a new stake in shares of Urogen Pharma in the third quarter worth $158,000. JPMorgan Chase & Co. acquired a new stake in shares of Urogen Pharma in the third quarter worth $168,000. GSA Capital Partners LLP acquired a new stake in shares of Urogen Pharma in the third quarter worth $293,000. Alps Advisors Inc. acquired a new stake in shares of Urogen Pharma in the second quarter worth $195,000. Finally, Shikiar Asset Management Inc. acquired a new stake in shares of Urogen Pharma in the third quarter worth $665,000. Hedge funds and other institutional investors own 34.71% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2017/12/05/urogen-pharma-urgn-rating-reiterated-by-cibc.html.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.